PROGENICS PHARMACEUTICALS IN - COM (PGNX)

CUSIP: 743187106

Q1 2019 13F Holders as of 31 Mar 2019

Type / Class
Equity / COM
Total 13F shares
68,380,216
Share change
-5,680,603
Total reported value
$317,298,194
Put/Call ratio
160%
Price per share
$4.64
Number of holders
137
Value change
-$21,632,781
Number of buys
75
Number of sells
51

Quarterly Holders Quick Answers

What is CUSIP 743187106?
CUSIP 743187106 identifies PGNX - PROGENICS PHARMACEUTICALS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of PROGENICS PHARMACEUTICALS IN - COM (PGNX) as of Q1 2019

As of 31 Mar 2019, PROGENICS PHARMACEUTICALS IN - COM (PGNX) was held by 137 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 68,380,216 shares. The largest 10 holders included BlackRock Inc., Point72 Asset Management, L.P., VANGUARD GROUP INC, STATE STREET CORP, EAGLE ASSET MANAGEMENT INC, FARALLON CAPITAL MANAGEMENT LLC, CARILLON TOWER ADVISERS, INC., RICE HALL JAMES & ASSOCIATES, LLC, PINNACLE ASSOCIATES LTD, and DEUTSCHE BANK AG\. This page lists 137 institutional shareholders reporting positions in this security for the Q1 2019 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.